# Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma

> **NCT05496036** · PHASE2 · RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 15 (estimated)

## Conditions studied

- Merkel Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05496036
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-13
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-09-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05496036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05496036, "Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05496036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*